Inorganic/Organic Nanocomposite Particles (I/O-NP); A Platform Technology for Next Generation Healthcare Applications

为了实现下一代潜在的纳米医学所提供的，必须开发下一代纳米材料。无机/有机纳米复合材料颗粒由聚合物、有机纳米级结构（50-200 nm）组成，其中封装有较小的金属纳米颗粒（2-20 nm）。有机和无机成分都可以变化，从而产生具有巨大合成潜力的平台技术。无机/有机纳米复合材料的使用尚处于起步阶段，但它们提供了一系列潜在的医疗保健应用，从增强癌症治疗的放射治疗到提供比目前已建立的技术更敏感，特异性和定量的诊断分析，以及生物系统潜力的实时监测和定量。这些材料可能有助于心血管成像，肿瘤学和细胞跟踪，但扩展到传染病诊断和先进的放射治疗将是世界领先的。无机/有机纳米复合颗粒将为纳米医学研究提供新的方向，为通过创建新型平台技术出现的新研究领域提供基础。对纳米复合材料的研究将为纳米复合材料开发和器件开发方面的研究创新开辟重要途径。独特的是，高度新颖的平台可以进一步采用，以结合响应功能，放大疾病靶向以及多种组分类型的结合，从而创建用于组合诊断和治疗的多功能复合材料。因此，该平台技术具有高度的适应性，允许在诊断和治疗领域的一系列应用，每个领域都有创新材料设计和设备开发的重要途径。该奖学金的具体目标是在英国创造世界领先的专业知识，能够开拓新的科学，并从其应用中建立对现实世界的医疗保健需求的影响。下一代纳米材料将带来新技术，为医疗诊断和治疗带来巨大好处。纳米材料开发战略是真正的多学科，因此，通过该奖学金，将建立多学科团队发展，以提供旨在将研究结果转化为临床应用的协作方法。通过这一战略，医疗保健研究的新领域将在英国建立真正的全球重要性。长远来说，建立一个平台技术的影响将提供一个跳板，申请人将从中发展商业和政策影响力，使他成为创新多学科研究的重要全球领导者。奖学金申请人Marco Giardiello博士在诊断和治疗领域都有无机和有机纳米医学研究的经验，在学术界和工业界建立了几个研究合作。他一直是纳米医学临床试验开发的识别和制造过程的关键领导者，并且在开发平台技术到商业产出方面不可或缺，共同创立了一家初创公司。这项研究将在利物浦大学化学系进行，并将进行跨院系、跨部门和多学科的合作。新型无机/有机纳米复合粒子的开发2.多学科研究团队建设3.新型纳米医学应用创造新的知识产权和工业监管成果4.将新技术应用于多种全球医疗保健需求

In order to achieve the next generation potential nanomedicine has to offer, next generation nanomaterials must be developed. Inorganic/organic nanocomposite particles are composed of polymeric, organic nanoscale structures (50-200 nm) in which smaller metallic nanoparticles (2-20 nm) are encapsulated. Both the organic and inorganic components can be varied, giving rise to a platform technology with great composition potential. The use of inorganic/organic nanocomposites is in its infancy, but they offer a range of potential healthcare applications, from enhancement of radiotherapy for cancer treatment to providing more sensitive, specific and quantitative diagnostic analysis than current established techniques, with real-time monitoring and quantification in biological systems potential. Such materials may aid cardiovascular imaging, oncology and cell tracking but extension to infectious disease diagnostics and advanced radiotherapy would be world-leading. Inorganic/organic nanocomposite particles will offer new direction for nanomedicine research, providing the foundation for new research fields to emerge through the creation of a novel platform technology. Investigation into nanocomposites will open significant avenues for research innovation in terms of both nanocomposite material development and device development. Uniquely, the highly novel platform could be further adopted to incorporate responsive functionality, amplified disease targeting as well as the incorporation of multiple component types, thus creating multifunctional composite materials for combinational diagnostics and therapy. The platform technology, therefore, is highly adaptable allowing for a range of applications in both diagnostic and therapeutic areas, each with significant avenues to innovative material design and device development. The specific aim of this fellowship is to enable the creation of world-leading expertise within the UK, able to pioneer new science and establish impact from its application towards real-world healthcare needs. Next generation nanomaterials will give rise to new technologies which would offer considerable benefits for healthcare diagnosis and for treatment. The nanomaterial development strategy is truly multidisciplinary and thus, through this fellowship, multidisciplinary team development will be established to provide collaborative approaches aimed at the translation of research findings to clinical use. Through this strategy, novel areas of healthcare research will be established in the UK with truly global importance. In the long-term, the impact of establishing a platform technology will provide a springboard from which the applicant will develop commercial and policy influence, enabling him to become a significant global leader of innovative multidisciplinary research.The fellowship applicant, Dr Marco Giardiello, has experience of inorganic and organic nanomedicine research in both diagnostic and therapeutic areas, having established several research collaborations in both academia and industry. He has been a key lead in the identification and manufacturing processes towards clinical trial development of nanomedicines, as well as being integral in developing platform technologies through to commercial outputs having co-founded a start-up company. The research is to be carried out at the University of Liverpool's Department of Chemistry with critical cross-faculty, cross-sector and multi-disciplinary collaboration.The fellowship proposal's key aims are:1. Novel inorganic/organic nanocomposite particle development2. Multidisciplinary research team building 3. Novel nanomedicine applications creating new IP and industrial regulatory engagement4. The application of new technologies towards multiple global healthcare needs